Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

79.29 +1.01 (+1.29%)
Official Closing Price Updated: 7:00 PM EDT, Jun 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 23,803,462
Open 78.05
Bid (Size) 79.00 (1)
Ask (Size) 79.45 (1)
Prev. Close 78.28
Today's Range 77.10 - 80.31
52wk Range 73.31 - 134.63
Shares Outstanding 2,531,374,696
Dividend Yield 4.09%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
2 Reasons to Watch MRK and 1 to Stay Cautious
Shareholders of Merck would probably like to forget the past six months even happened. The stock dropped 20.3% and now trades at $79.30. This might have investors contemplating their next move. 
Via StockStory
Topics Supply Chain
Exposures Supply Chain
Nobody Wants To Touch Healthcare Stocks Now – That Might Be A Big Mistake
Healthcare stocks are lagging the market by the widest margin since 2008. Analysts and valuation trends point to a rebound. 
Via Benzinga

Performance

YTD
-20.0%
-20.0%
1 Month
+2.7%
+2.7%
3 Month
-15.7%
-15.7%
6 Month
-19.4%
-19.4%
1 Year
-38.0%
-38.0%

More News

Read More
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
MERCK & CO. INC. (NYSE:MRK) - A Strong Dividend Stock with Solid Fundamentals
Via Chartmill
Price Over Earnings Overview: Merck & Co
Via Benzinga
IDeate-Prostate01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Pretreated Metastatic Castration-Resistant Prostate Cancer
From Merck & Co., Inc.
Via Business Wire
2 Dividend Stocks to Buy and Never Sell
Via The Motley Fool
Topics Lawsuit
Exposures Financial Legal
3 Mega-Cap Stocks with Competitive Advantages
Via StockStory
Elizabeth Warren, Jan Schakowsky Reportedly Seek Answers From Pfizer, Amgen, And Others On Low Federal Tax Bills
Via Stocktwits
Topics Government
Exposures Political
These Were the 2 Worst-Performing Stocks in the Dow Jones Industrial Average in May 2025
Via The Motley Fool
Topics Government Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
Merck's Keytruda Secures FDA Nod For Head And Neck Cancer As First Immunotherapy For Use Around Surgery
Via Benzinga
Exposures Product Safety
Merck Gets FDA Approval For Keytruda To Treat A Broader Population Of Head And Neck Cancer Patients: Retail Stays Bullish
Via Stocktwits
Topics Death
Exposures Death Product Safety
FDA Approves KEYTRUDA® (pembrolizumab) for PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy With or Without Cisplatin Then as a Single Agent
From Merck & Co., Inc.
Via Business Wire
Merck Animal Health Receives EU CVMP Positive Opinion for NUMELVI™ (atinvicitinib) Tablets for Dogs
From Merck & Co., Inc.
Via Business Wire
RFK Jr. Appointee To CDC Advisory Committee Was A Paid Expert In Merck's Gardasil Lawsuit
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate
From Merck & Co., Inc.
Via Business Wire
2 Unstoppable Stocks to Consider Buying, Even Amid Market Volatility
Via The Motley Fool
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
Unpacking the Latest Options Trading Trends in Merck & Co
Via Benzinga
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?
Via The Motley Fool
Topics Stocks
Exposures US Equities
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
MERCK & CO. INC. (NYSE:MRK) - A Strong Value Pick in Pharmaceuticals
Via Chartmill
U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season
From Merck & Co., Inc.
Via Business Wire
Merck's Cholesterol Lowering Drug Hits Primary Goal In Two Pivotal Trials
Via Benzinga
Merck Announces Positive Data From Trials For Cholesterol Drug, But Retail Reaction Is Sluggish
Via Stocktwits

Frequently Asked Questions

Is Merck & Co publicly traded?
Yes, Merck & Co is publicly traded.
What exchange does Merck & Co trade on?
Merck & Co trades on the New York Stock Exchange
What is the ticker symbol for Merck & Co?
The ticker symbol for Merck & Co is MRK on the New York Stock Exchange
What is the current price of Merck & Co?
The current price of Merck & Co is 79.29
When was Merck & Co last traded?
The last trade of Merck & Co was at 06/18/25 07:00 PM ET
What is the market capitalization of Merck & Co?
The market capitalization of Merck & Co is 200.71B
How many shares of Merck & Co are outstanding?
Merck & Co has 201B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.